[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.211.207.116. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Letters
July 28, 1999

Alendronate and Fracture Prevention

Author Affiliations
 

Margaret A.WinkerMD, Deputy EditorIndividualAuthorPhil B.FontanarosaMD, Interim CoeditorIndividualAuthor

JAMA. 1999;282(4):324-325. doi:10-1001/pubs.JAMA-ISSN-0098-7484-282-4-jbk0728

To the Editor: The Editorial by Dr Heaney1 concludes that 4 years of treatment with alendronate sodium produced disappointing results for women with low bone density. It may be too much to expect that only 4 years of modest increases in bone density with alendronate, estrogen, tamoxifen citrate, or other agents would reduce nonspine fracture risk in women with only a modest risk.24 However, this should not obscure the important finding that just 3 to 4 years of alendronate substantially reduced the risk of painful fractures in women who have hip bone density at least 2.5 SDs below normal. These findings reinforce National Osteoporosis Foundation guidelines5 that women 65 years and older who are willing to consider treatment for osteoporosis should have a measurement of bone density to determine whether they would benefit from treatment.

First Page Preview View Large
First page PDF preview
First page PDF preview
×